BRIEF—ICER draft report on inotersen and patisiran for HTA

The USA’s Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness of inotersen from Akcea Therapeutics and patisiran from Alnylam Pharmaceuticals  for hereditary transthyretin-related amyloidosis (HTA), a rare genetic condition that can affect multiple organ systems.

The report from the medicines cost-effectiveness organizaton, along with accompanying draft voting questions, will be open to public comment until August 17, 2018.

Findings contained in this report are preliminary and subject to change based on additional stakeholder input and further analysis of data.

The report will be subject to deliberation during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council, one of ICER’s three independent evidence appraisal committees, in September of 2018.